News
The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials ...
President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...
Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...
Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, ...
Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.
Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID ...
The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.
WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results